<?xml-stylesheet type='text/xsl' href='ctgovTransform.xsl'?>
<CT.GOV_Trial requestNumber="6507">
  <stage>Registered</stage>
  <submitdate>13/06/2016</submitdate>
  <approvaldate>13/06/2016</approvaldate>
  <nctid>NCT02833844</nctid>
  <trial_identification>
    <studytitle>Safety, Tolerability &amp; Efficacy on LDL-C of Evolocumab in Subjects With HIV &amp; Hyperlipidemia/Mixed Dyslipidemia</studytitle>
    <scientifictitle>A Double Blind, Randomized, Placebo Controlled, Multicenter Study to Evaluate Safety, Tolerability, and Efficacy on LDL-C of Evolocumab (AMG 145) in Subjects With HIV and With Hyperlipidemia and/or Mixed Dyslipidemia</scientifictitle>
    <utrn />
    <trialacronym />
    <secondaryid>2015-004735-12</secondaryid>
    <secondaryid>20130286</secondaryid>
  </trial_identification>
  <conditions>
    <healthcondition>Subjects With Hyperlipidemia, Dyslipidemia and HIV Infection</healthcondition>
    <conditioncode>
      <conditioncode1>Infection</conditioncode1>
      <conditioncode2>Acquired immune deficiency syndrome (AIDS / HIV)</conditioncode2>
    </conditioncode>
    <conditioncode>
      <conditioncode1>Cardiovascular </conditioncode1>
      <conditioncode2>Other cardiovascular diseases</conditioncode2>
    </conditioncode>
    <conditioncode>
      <conditioncode1>Blood </conditioncode1>
      <conditioncode2>Other blood disorders</conditioncode2>
    </conditioncode>
    <conditioncode>
      <conditioncode1>Metabolic and Endocrine</conditioncode1>
      <conditioncode2>Other metabolic disorders</conditioncode2>
    </conditioncode>
  </conditions>
  <interventions>
    <interventions>Treatment: drugs - Repatha (Evolocumab)
Treatment: drugs - Placebo
Treatment: drugs - Repatha (Evolocumab)

Experimental: 24-week Double Blind Period Repatha (Evolocumab) - Repatha (Evolocumab) subcutaneous injection every 4 weeks (QM)

Placebo Comparator: 24-week Double Blind Period Repatha (Evolocumab) Placebo - Repatha (Evolocumab) Matching Placebo subcutaneous injection every 4 weeks (QM)

Experimental: 24-week Open Label Period Repatha (Evolocumab) - Repatha (Evolocumab) subcutaneous injection every 4 weeks (QM)


Treatment: drugs: Repatha (Evolocumab)
Dose of subcutaneous Repatha (Evolocumab) every 4 weeks (QM)

Treatment: drugs: Placebo
Dose of subcutaneous Repatha (Evolocumab) Matching Placebo every 4 weeks (QM)

Treatment: drugs: Repatha (Evolocumab)
Dose of subcutaneous Repatha (Evolocumab) every 4 weeks (QM)

</interventions>
    <comparator />
    <control />
    <interventioncode>Treatment: drugs</interventioncode>
  </interventions>
  <outcomes>
    <primaryOutcome>
      <outcome>Effect of Repatha (Evolocumab) on percent change from baseline in low-density lipoprotein cholesterol (LDL-C) in human immunodeficiency virus (HIV)-positive subjects with hyperlipidemia or mixed dyslipidemia - HIV = human immunodeficiency virus</outcome>
      <timepoint>Week 24</timepoint>
    </primaryOutcome>
    <secondaryOutcome>
      <outcome>Effect of Repatha (Evolocumab) on change from baseline in LDL-C in HIV-positive subjects with hyperlipidemia or mixed dyslipidemia - LDL-C=low-density lipoprotein cholesterol</outcome>
      <timepoint>Week 24</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Effect of Repatha (Evolocumab) on percent of subjects attaining LDL-C &lt; 70 mg/dL (1.8 mmol/L) in HIV-positive subjects with hyperlipidemia or mixed dyslipidemia - LDL-C=low-density lipoprotein cholesterol</outcome>
      <timepoint>Week 24</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Effect of Repatha (Evolocumab) on percent of subjects attaining a 50% reduction in LDL-C from baseline in HIV-positive subjects with hyperlipidemia or mixed dyslipidemia - LDL-C=low-density lipoprotein cholesterol</outcome>
      <timepoint>Week 24</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Effect of Repatha (Evolocumab) on percent change from baseline in ApoB in HIV-positive subjects with hyperlipidemia or mixed dyslipidemia - ApoB=apolipoprotein B</outcome>
      <timepoint>Week 24</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Effect of Repatha (Evolocumab) on percent change from baseline in TC in HIV-positive subjects with hyperlipidemia or mixed dyslipidemia - TC=total cholesterol</outcome>
      <timepoint>Week 24</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Effect of Repatha (Evolocumab) on percent chang from baseline in Lp(a) in HIV-positive subjects with hyperlipidemia or mixed dyslipidemia - Lp(a)=lipoprotein(a)</outcome>
      <timepoint>Week 24</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Effect of Repatha (Evolocumab) on percent change from baseline in triglycerides in HIV-positive subjects with hyperlipidemia or mixed dyslipidemia</outcome>
      <timepoint>Week 24</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Effect of Repatha (Evolocumab) on percent change from baseline in HDL-C in HIV-positive subjects with hyperlipidemia or mixed dyslipidemia - HDL-C=high-density lipoprotein cholesterol</outcome>
      <timepoint>Week 24</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Effect of Repatha (Evolocumab) on percent change from baseline in non-HDL-C in HIV-positive subjects with hyperlipidemia or mixed dyslipidemia - non-HDL-C=non-high-density lipoprotein cholesterol</outcome>
      <timepoint>Week 24</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Effect of Repatha (Evolocumab) on percent change from baseline in VLDL-C in HIV-positive subjects with hyperlipidemia or mixed dyslipidemia - VLDL-C=very low-density lipoprotein cholesterol</outcome>
      <timepoint>Week 24</timepoint>
    </secondaryOutcome>
  </outcomes>
  <eligibility>
    <inclusivecriteria>-  Male or female = 18 years of age

          -  Known HIV (human immunodeficiency virus) infection with stable HIV therapy for = 6
             months

          -  Cluster of differentiation 4 (CD4) = 250 cells/mm3 for = 6 months

          -  HIV viral load = 50 copies/mL at screening and = 200 copies/mL for = 6 months

          -  Subject on stable lipid-lowering therapy for = 4 weeks prior to randomization and not
             expected to change during the duration of study

          -  For subjects with known clinical astherosclerotic CVD (ASCVD), fasting LDL-C of = 70
             mg/dL or non-HDL-C = 100 mg/dL. For subjects without known clinical ASCVD: fasting
             LDL-C of = 100 mg/dL or non-HDL-C of = 130 mg/dL

          -  Fasting triglycerides = 600 mg/dL (6.8 mmol/L)</inclusivecriteria>
    <inclusiveminage>18</inclusiveminage>
    <inclusiveminagetype>Years</inclusiveminagetype>
    <inclusivemaxage />
    <inclusivemaxagetype>No limit</inclusivemaxagetype>
    <inclusivegender>Both males and females</inclusivegender>
    <healthyvolunteer>No</healthyvolunteer>
    <exclusivecriteria>-  Taking a combination of background lipid-lowering therapy and HIV therapy known to
             have significant drug-drug interaction

          -  NYHA III or IV heart failure, or last known left ventricular ejection fraction (LVEF)
             &lt; 30%

          -  Known opportunistic infection/AIDS defining illness within 1 year prior to
             randomization

          -  Myocardial infarction, unstable angina, percutaneous coronary intervention,coronary
             artery bypass graft or stroke within 3 months

          -  Type 1 diabetes, new-onset or poorly controlled type 2 diabetes

          -  Uncontrolled hypertension

          -  Taken a cholesterylester transfer protein inhibitor in the last 12 months

          -  Moderate to severe renal dysfunction

          -  Persistent active liver disease or hepatic dysfunction (Stable chronic hepatitis C of
             at least 1 year duration prior to randomization is allowed)

          -  Malignancy (except non-melanoma skin cancers, cervical in-situ carcinoma,breast ductal
             carcinoma in situ, or stage 1 prostate carcinoma) within the last 5 years prior to
             randomization,

          -  Other Exclusion Criteria May Apply.</exclusivecriteria>
  </eligibility>
  <trial_design>
    <studytype>Interventional</studytype>
    <purpose>Treatment</purpose>
    <allocation>Randomised controlled trial</allocation>
    <concealment />
    <sequence />
    <masking>Blinded (masking used)</masking>
    <assignment>Parallel</assignment>
    <designfeatures />
    <endpoint />
    <statisticalmethods />
    <masking1>The people receiving the treatment/s</masking1>
    <masking2>The people administering the treatment/s</masking2>
    <masking3>The people assessing the outcomes</masking3>
    <masking4>The people analysing the results/data</masking4>
    <patientregistry />
    <followup />
    <followuptype />
    <purposeobs />
    <duration />
    <selection />
    <timing />
  </trial_design>
  <recruitment>
    <phase>Phase 3</phase>
    <anticipatedstartdate />
    <actualstartdate>22/05/2017</actualstartdate>
    <anticipatedenddate />
    <actualenddate />
    <samplesize>450</samplesize>
    <actualsamplesize />
    <recruitmentstatus>Recruiting</recruitmentstatus>
    <anticipatedlastvisitdate>7/02/2020</anticipatedlastvisitdate>
    <actuallastvisitdate />
    <dataanalysis />
    <withdrawnreason />
    <withdrawnreasonother />
    <recruitmentcountry>Australia</recruitmentcountry>
    <recruitmentstate>NSW,QLD,VIC</recruitmentstate>
    <hospital>Research Site - Darlinghurst</hospital>
    <hospital>Research Site - East Sydney</hospital>
    <hospital>Research Site - Sydney</hospital>
    <hospital>Research Site - Fortitude Valley</hospital>
    <hospital>Research Site - Melbourne</hospital>
    <hospital>Research Site - Prahran</hospital>
    <postcode>2010 - Darlinghurst</postcode>
    <postcode>2010 - East Sydney</postcode>
    <postcode>2010 - Sydney</postcode>
    <postcode>4006 - Fortitude Valley</postcode>
    <postcode>3004 - Melbourne</postcode>
    <postcode>3181 - Prahran</postcode>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>California</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Connecticut</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>District of Columbia</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Florida</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Georgia</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Michigan</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Minnesota</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Missouri</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>New York</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Ohio</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Virginia</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Belgium</country>
      <state>Antwerp</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Belgium</country>
      <state>Brussels</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Belgium</country>
      <state>Gent</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Canada</country>
      <state>Alberta</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Canada</country>
      <state>British Columbia</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Canada</country>
      <state>Ontario</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Canada</country>
      <state>Quebec</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>France</country>
      <state>Bordeaux</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>France</country>
      <state>Lyon cedex 04</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>France</country>
      <state>Montpellier cedex 5</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>France</country>
      <state>Nantes Cedex 1</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>France</country>
      <state>Paris Cedex 12</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>France</country>
      <state>Paris Cedex 13</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Greece</country>
      <state>Athens</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Greece</country>
      <state>Thessaloniki</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Italy</country>
      <state>Bologna</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Italy</country>
      <state>Genova</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Italy</country>
      <state>Modena</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Italy</country>
      <state>Roma</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Poland</country>
      <state>Krakow</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Poland</country>
      <state>Wroclaw</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Portugal</country>
      <state>Aveiro</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Portugal</country>
      <state>Coimbra</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Portugal</country>
      <state>Porto</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Romania</country>
      <state>Bucharest</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Romania</country>
      <state>Constanta</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Romania</country>
      <state>Timisoara</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>South Africa</country>
      <state>Bloemfontein</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Spain</country>
      <state>Cataluña</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Spain</country>
      <state>Madrid</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Switzerland</country>
      <state>Geneva 14</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Switzerland</country>
      <state>Lausanne</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Switzerland</country>
      <state>Lugano</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Switzerland</country>
      <state>Zuerich</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United Kingdom</country>
      <state>London</state>
    </countryoutsideaustralia>
  </recruitment>
  <sponsorship>
    <primarysponsortype>Commercial sector/Commercial sector/Industry</primarysponsortype>
    <primarysponsorname>Amgen</primarysponsorname>
    <primarysponsoraddress />
    <primarysponsorcountry />
  </sponsorship>
  <ethicsAndSummary>
    <summary>The study is divided into 2 parts. The first part of the study will be double-blinded and
      will last for 24 weeks. During this time, subjects will be randomized in a ratio of 2:1 to
      receive either Repatha (evolocumab) QM or placebo QM.

      The second part of the study is a 24-week open label extension period. During this time all
      subjects will receive Repatha (evolocumab) QM.

      The clinical hypothesis is that subcutaneous Repatha (evolocumab) QM will be well tolerated
      and will result in greater reduction of LDL-C, defined as percent change from baseline at
      week 24, compared with placebo QM in HIV-positive subjects with hyperlipidemia or mixed
      dyslipidemia.</summary>
    <trialwebsite>https://clinicaltrials.gov/show/NCT02833844</trialwebsite>
    <publication />
    <ethicsreview />
    <publicnotes />
  </ethicsAndSummary>
  <attachment />
  <contacts>
    <contact>
      <title />
      <name>MD</name>
      <address>Amgen</address>
      <phone />
      <fax />
      <email />
      <country />
      <type>Principal Investigator</type>
    </contact>
    <contact>
      <title />
      <name>Amgen Call Center</name>
      <address />
      <phone>866-572-6436</phone>
      <fax />
      <email>medinfo@amgen.com</email>
      <country />
      <type>Public Queries</type>
    </contact>
  </contacts>
</CT.GOV_Trial>